D-0836-2022 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-0836-2022 was initiated by Macleods Pharma Usa Inc on Apr 15, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated Oct 13, 2023).

Recall details

Product Type
Drugs
Report Date
May 11, 2022
Initiation Date
Apr 15, 2022
Termination Date
Oct 13, 2023
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/25 mg, a) 30-count bottles (NDC# 33342-052-07), b) 90-count bottles (NDC # 33342-052-10) c) 1000-count bottles (NDC # 33342-052-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Distribution pattern

Product was distributed nationwide.

Code information

Lot # BLM2106B, exp. date 05/2023 BLM2101A, exp. date 01/2025 BLM2102A, exp. date 02/2023 BLM2106A, exp. date 05/2023 BLM2103B, exp. date 02/2023 BLM2104A, exp. date 05/2023 BLM2110A, exp. date 06/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0836-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0836-2022. Report a data issue: hello@regdatalab.com.